Following a single, oral administration of carvedilol and nebivolol, a tendency was observed for reduction of mean values of vascular flow in the iris and retina/choroid in study groups, but differences between study groups and the control was not statistically significant.
In general, there was no statistically significant difference in body temperature between the study groups, but there was a significant difference between Group I and the study groups (p < 0.001).
For none of these measures did we detect a statistical difference between the study groups, but further studies should utilize a simethicone placebo.
The reports from veterinarian and technicians should not differ between the study groups, but there could be differences in the willingness to report amongst the farmers causing information bias.
Given our relatively small sample size, we were surprised to find such clear differences between our study groups, but in the future, it will be important to perform larger and more powerful longitudinal studies on patients with DS and AD to track the dynamics of DNA methylation changes during cognitive decline.
Disease characteristics and antirheumatic medications at baseline were well balanced between the study groups, but the cumulative burden of disease within 2 years after inclusion was lower in patients treated with prednisolone except for AUC-CRP, as compared with those who did not receive prednisolone.
Missing data due to loss of follow up (eg undelivered surveys) was equally distributed between study groups in two studies [ 26, 28], but this information was not reported in the other two studies [ 11, 27].
Double-masked, controlled trials, usually with placebos, are the accepted gold standard in investigating new drugs and treatments because they have proved to be the best way to minimize investigator bias and error and maximize similarities between study groups.
